Doctor Strange Reaches New Box Office Heights, Not Expected to Make $1 Billion

Marvel's newest superhero movie, Doctor Strange, has now crossed $100 million at the US box office. The milestone was reached today, November 9, which is six days after the film premiered stateside.

At $100 million, Doctor Strange is the second highest-grossing fall movie of 2016, behind only the Tom Hanks film, Sully ($123.3 million).

According to Deadline, Doctor Strange is poised to rule the US box office for a second straight weekend, with projections of $40 million-$42 million for the November 11-13 window. That would be a 52 percent decline from the movie's opening weekend haul of $85 million.

Globally, Doctor Strange passed $325 million as of Tuesday afternoon, according to Deadline. Sources told the site that the movie is unlikely to join the elite club of Marvel movies that have made $1 billion, however. Those include The Avengers ($1.5 billion), The Avengers: Age of Ultron ($1.4 billion), Iron Man 3 ($1.2 billion), and Captain America: Civil War ($1.15 billion).

Doctor Strange is projected to finish in the $750 million-$850 million range, making it one of 2016 biggest releases at the box office. According to Box Office Mojo, the movie had a $165 million budget.

It's been a big year for Disney, as the company's movies have so far made more than $6 billion at the global box office, a new high mark. That's not an industry record, however. Universal's box office take for 2015 ended with $6.89 billion, fueled in part by the massive success of Jurassic World, the fourth-biggest movie in film history.

Disney could pass Universal's record this year, as it still has big-time movies on the way including Moana and Star Wars: Rogue One. Disney's biggest hits this year include Captain America: Civil War ($1.15 billion), Finding Dory ($1.024 billion), Zootopia ($1.023 billion), and The Jungle Book ($966 million), while Doctor Strange will be another major contributor.

For more on Doctor Strange, check out GameSpot's review and what other critics are saying.